PART I Overview We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects. Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001104659-26-028068 | EDGAR | 95K words |
| 2025-03-25 | 2024-12-31 | 0001558370-25-003588 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001558370-24-003886 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001558370-23-005126 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0001558370-22-003671 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001558370-21-003083 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001558370-20-003257 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-109867 | EDGAR | 61K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011152 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007667 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014767 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001558370-24-011806 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008069 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001558370-23-018572 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001558370-23-014405 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009887 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017205 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001558370-22-013512 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001558370-22-008955 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-23 | 0001104659-26-086254 | EDGAR | — |
| 2026-04-01 | 0001104659-26-038258 | EDGAR | 1K words |
| 2026-03-30 | 0001104659-26-036821 | EDGAR | — |
| 2026-03-16 | 0001104659-26-028046 | EDGAR | — |
| 2026-02-18 | 0001104659-26-016797 | EDGAR | — |
| 2026-01-29 | 0001104659-26-007988 | EDGAR | — |
| 2026-01-23 | 0001104659-26-006267 | EDGAR | — |
| 2026-01-09 | 0001104659-26-002490 | EDGAR | — |
| 2025-12-09 | 0001104659-25-119680 | EDGAR | — |
| 2025-11-12 | 0001104659-25-109860 | EDGAR | — |
140 total filings indexed. 111 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001781983 |
| Ticker | APRE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.aprea.com |
| Listed | 2019-10-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/APRE (~200 tokens, structured JSON with cryptographic provenance)